GlassScriptPhysician profile
Celina Navarro
NPI 1134755226
$5,058.65
in general payments reported to CMS, 2019-2025
30 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what 89% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $573 · 2022: $582 · 2023: $1,564 · 2024: $1,035 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927 · Travel and Lodging: $904 · Education: $73.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.56 |
| Travel and Lodging | $903.69 |
| Education | $73.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,295.43 | 2023-2024 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $818.89 | 2021-2025 | Vumerity, Spinraza |
| Ucb, INC. | $383.96 | 2021-2025 | Briviact, Nayzilam, Fintepla |
| Abbvie INC. | $343.14 | 2024-2025 | |
| Emd Serono, INC. | $286.34 | 2021-2024 | Mavenclad |
| Genentech USA, INC. | $244.23 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Argenx US, INC. | $213.91 | 2024-2025 | Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $162.69 | 2023-2025 | Ultomiris, Soliris |
| Neurelis, INC. | $124.66 | 2024-2025 | Valtoco |
| Genzyme Corporation | $121.87 | 2021 | |
| Jazz Pharmaceuticals INC. | $119.37 | 2023-2025 | |
| Horizon Therapeutics Plc | $114.78 | 2021 | |
| Tanabe Pharma America, INC. | $110.08 | 2023-2025 | Radicava |
| Medtronic, INC. | $69.21 | 2024-2025 | Percept PC Brainsense |
| Catalyst Pharmaceuticals, INC. | $68.19 | 2023-2024 | Fycompa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $68.07 | 2023 | Ingrezza, Ongentys |
| Janssen Biotech, INC. | $54.96 | 2025 | |
| Sk Life Science, INC. | $54.04 | 2025 | Xcopri |
| Merz Pharmaceuticals, LLC | $49.31 | 2025 | Xeomin, Inbrija |
| Pfizer INC. | $49.03 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $46.05 | 2022-2023 | |
| Route 92 Medical, INC. | $44.88 | 2024 | 8f Base Camp Sheath System |
| Ipsen Biopharmaceuticals, INC | $42.07 | 2024-2025 | Dysport |
| Csl Behring | $38.66 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.77 | 2025 | Zeposia |
| Lundbeck LLC | $29.33 | 2025 | Vyepti |
| Amylyx Pharmaceuticals, INC. | $25.92 | 2024 | Relyvrio |
| Biohaven Pharmaceuticals, INC. | $20.31 | 2021 | |
| Lilly USA, LLC | $16.06 | 2025 | Kisunla |
| Amneal Pharmaceuticals LLC | $13.44 | 2024 | Rytary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celina Navarro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.